WCLC 2025 - Posters & ePosters-EP.18.01 The Beneficial Value of 18F FDG PET/CT in the Follow-Up of Stage III Non-Small Cell Lung Cancer Patients (NVALT31-PET Study)

EP.18.01 The Beneficial Value of 18F FDG PET/CT in the Follow-Up of Stage III Non-Small Cell Lung Cancer Patients (NVALT31-PET Study)

Back to course

Pdf Summary

The NVALT31-PET study is an ongoing multicenter randomized controlled trial investigating the benefit of [F] FDG PET/CT compared to conventional CT surveillance during follow-up of stage III non-small cell lung cancer (NSCLC) patients treated with curative intent. Despite advances in treatment, stage III NSCLC patients have a high recurrence risk of 50-78%, including local recurrence (22-50%) and distant metastases (48-78%). Early detection of oligometastases is critical for potential curative re-treatment.<br /><br />The primary aim is to assess the impact of PET/CT versus CT surveillance on 3-year overall survival. Secondary objectives include evaluating recurrence detection rates, health-related quality of life, treatment types after recurrence, fear of cancer recurrence, event-free survival, the role of circulating tumor DNA (ctDNA) in recurrence detection, and cost-effectiveness.<br /><br />The trial randomizes 690 patients 1:1, stratified by histology and treatment type, with intention-to-treat analysis planned using Kaplan-Meier survival curves. Preliminary baseline data from 237 patients show comparable groups in age (~67 years), sex distribution, ECOG performance status, histology (majority adenocarcinoma and squamous cell carcinoma), and primary curative treatments (mainly chemoradiation with or without immunotherapy, surgery, and radiotherapy). Recruitment continues with first results expected by the end of 2029.<br /><br />This trial seeks to clarify whether PET/CT surveillance improves survival outcomes and other clinical endpoints in stage III NSCLC during follow-up compared to standard CT, potentially influencing future surveillance strategies.<br /><br />For further details, contact Nicole Billingy at Radboudumc or access the study protocol via provided contacts.

Asset Subtitle

Nicole Billingy

Meta Tag

Speaker Nicole Billingy

Topic Clinical Trials in Progress

Keywords

NVALT31-PET study

stage III non-small cell lung cancer

NSCLC

FDG PET/CT

CT surveillance

randomized controlled trial

overall survival

recurrence detection

circulating tumor DNA

chemoradiation